Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
55 hedge funds and large institutions have $55.2M invested in Infinity Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 14 closing their positions.
1,333% more call options, than puts
Call options by funds: $86K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $58.1M → $55.2M (-$2.93M)
13% less funds holding
Funds holding: 63 → 55 (-8)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$178K |
| 2 |
AC
Athanor Capital
New York
|
+$158K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$95K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$87.6K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$67.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$337K |
| 2 |
Millennium Management
New York
|
-$213K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$129K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$96.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$59.8K |
INFI Hedge Fund Activity: Q2 2019 in Review
55 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2019, worth a combined $55.2M — down 5% from $58.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of INFI and 6 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $178K. The largest seller was JP Morgan Chase, cutting an estimated $337K.
- 55 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2019, down from 63 in Q1 2019.
- Funds reported $55.2M of Infinity Pharmaceuticals, Inc. stock for Q2 2019, down 5% quarter-over-quarter.
- 6 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2019 and 14 closed out, a net change of -8 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2019 was Renaissance Technologies, an estimated $178K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2019 was JP Morgan Chase, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2019.